Withdrawal of hospital outpatient treatments in severe diseases due to unacceptable toxicity: A retrospective study from the register of patients and treatments.

British Journal of Clinical Pharmacology
Antònia AgustíEduard Diogène

Abstract

To retrospectively analyse hospital outpatient treatment (HOT) withdrawal due to unacceptable toxicity at our hospital. Information regarding unacceptable toxicity leading to treatment withdrawal was recorded. HOT interruptions because of unacceptable toxicity were identified from the Register of Patients and Treatments (RPT) (January 2014 to December 2017). Information regarding the demographic and clinical characteristics of patients, adverse drug reactions (ADRs) and drug treatments was retrieved from electronic health records. Causality and previous knowledge of ADRs were assessed according to the Spanish Pharmacovigilance System algorithm. Information regarding HOT risk management plans (RMPs) and their classification as inverted black triangle medicines was obtained from the European Medicines Agency (EMA). HOTs were withdrawn due to unacceptable toxicity in 136 (1.5%) registries corresponding to 135 (1.7%) patients. Fifty-one different HOTs (38.6% of those registered) were involved in 240 ADR/HOT pairs: 24 (47%) were additional monitoring medicines and 37 (72.5%) were EMA RMPs. The most frequent medicines involved in ADRs were lenalidomide (30, 12.5%) (mainly neutropenia, thrombocytopenia and bicytopenia), bevacizumab (1...Continue Reading

References

May 13, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Lorna Hazell, Saad A W Shakir
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Jan 10, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Consuelo PedrósJosep M Arnau
Nov 19, 2010·BMC Research Notes·Antonio VallanoJosep Maria Arnau
Jan 12, 2011·British Journal of Clinical Pharmacology·Isa Naina MohamedJames S McLay
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Feb 5, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Preciosa M ColomaMiriam Sturkenboom
May 4, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Cristian Gonzalez-GonzalezAdolfo Figueiras
May 25, 2013·Pharmacoepidemiology and Drug Safety·B WettermarkHt Sørensen
Jun 26, 2013·Joint Commission Journal on Quality and Patient Safety·Elizabeth W PaxtonMaria C S Inacio
Dec 10, 2015·International Journal of Technology Assessment in Health Care·Simona MontillaLuca Pani
Mar 2, 2016·BMC Medical Informatics and Decision Making·Inês Ribeiro-VazRicardo Cruz-Correia
Oct 1, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gianluca TrifiròGiovanni Corrao
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Feifan LiuHong Yu
Nov 25, 2019·Medicina clínica·Marta Roig IzquierdoCaridad Pontes García
Jan 15, 2020·European Journal of Clinical Pharmacology·Camille AzamFlorent Puisset
Jan 25, 2020·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Minoru MiyashitaHiroji Iwata

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.